An update on molecular biology of thyroid cancers

Critical Reviews in Oncology/Hematology

Volumn 90, Issue 3, 2014, Pages 233-252

  Omur, Ozgur ^a   Baran, Yusuf ^b  

^a EGE UNIVERSITY   (Turkey)

^b IZMIR INSTITUTE OF TECHNOLOGY   (Turkey)

Author keywords

BRAF; Differentiated thyroid cancer; Molecular biology; PAX8 PPAR ; RET PTC; Thyroid cancer

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; AXITINIB; B RAF KINASE; BETA CATENIN; EVEROLIMUS; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LBT 613; LENVATINIB; MICRORNA; MICRORNA 146B; MICRORNA 221; MICRORNA 222; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PROTEIN KINASE B; PROTEIN P53; PROTEIN RET; RAS PROTEIN; SORAFENIB; SU 12248; SUNITINIB; TRANSCRIPTION FACTOR PAX8; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VORINOSTAT; WNT PROTEIN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; GENE TARGETING; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; THYROID CANCER; TUMOR DIFFERENTIATION; TUMOR GENE; ANIMAL; DRUG EFFECTS; GENETICS; METABOLISM; THYROID NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84899917464     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.12.007     Document Type: Review

References (287)

1. DeLellis R.A., Lloyd R.V., Heitz P.U., Eng C. World Health Organization classification of tumors. Pathology and genetics of tumors of endocrine organs 2004, IARC Press, Lyon.
2. Cooper D.S., Doherty G.M., Haugen B.R., et al. (American Thyroid Association Guidelines Taskforce) management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006, 16:109-141.
3. Pitoia F., Bueno F., Urciuoli C., Abelleira E., Cross G., Tuttle R.M. Outcome of patients with differentiated thyroid cancer risk stratified according to the American Thyroid Association and Latin American Thyroid Society risk of recurrence classification systems. Thyroid 2013, 23(11):1401-1407.
4. Pellegriti G., Frasca F., Regalbuto C., Squatrito S., Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013 2013, 1-10.
5. Kilfoy B.A., Zheng T., Holford T.R., et al. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 2009, 20:525-531.
6. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics 2010. CA: Cancer J Clin 2010, 60:277-300.
7. Kent W.D.T., Hall S.F., Isotalo P.A., Houlden R.L., George R.L., Groome P.A. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. Can Med Assoc J 2007, 177:1357-1361.
8. Jemal A., Murray T., Ward E., et al. 2005 Cancer statistics. CA Cancer J Clin 2005, 55:10-30.
9. Sherman S.I. Thyroid carcinoma. Lancet 2003, 361:501-511.
10. Randolph G.W., Duh Q.Y., Heller K.S., et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 2012, 22:1144-1152.
11. Yu X.M., Lloyd R., Chen H. Current treatment of papillary thyroid microcarcinoma. Adv Surg 2012, 46:191-203.
12. Meas T., Vercellino L., Faugeron I., Toubert M.E. The 2009 Revised American Thyroid Association Guidelines for Thyroid Cancer: multifocality in T1 tumors in question, for or against a more minimalist approach?. Thyroid 2013, 23(8):1042-1043.
13. Lee S.L. Radioactive iodine therapy. Curr Opin Endocrinol Diabetes Obes 2012, 19:420-428.
14. Nikiforov Y.E. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 2008, 21:S37-S43.
15. Witt R.L., Ferris R.L., Pribitkin E.A., Sherman S.I., Steward D.L., Nikiforov Y.E. Diagnosis and management of differentiated thyroid cancer using molecular biology. Laryngoscope 2013, 123:1059-1064.
16. Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E., Fagin J.A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003, 63:1454-1457.
17. Fagin J.A. Genetics of papillary thyroid cancer initiation: implications for therapy. Trans Am Clin Climatol Assoc 2005, 116:259-269.
18. Luster M., Hänscheid H., Freudenberg L.S., Verburg F.A. Radioiodine therapy of metastatic lesions of differentiated thyroid cancer. J Endocrinol Invest 2012, 35:21-29.
19. Molinaro E., Pieruzzi L., Viola D. Radioiodine post-surgical remnant ablation in patients with differentiated thyroid cancer: news from the last 10 years. J Endocrinol Invest 2012, 35:16-20.
20. Boos L.A., Dettmer M., Schmitt A., et al. Diagnostic and prognostic implications of the PAX8-PPARγ translocation in thyroid carcinomas-a TMA-based study of 226 cases. Histopathology 2013.
21. Goyal N., Setabutr D., Abdulghani J., Goldenberg D. Molecular and genetic markers of follicular-cell thyroid cancer: etiology and diagnostic and therapeutic opportunities. Adv Exp Med Biol 2013, 779:309-326.
22. Dai G., Levy O., Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996, 379:458-460.
23. Eskandari S., Loo D.D.F., Dai G., Levy O., Wright E.M., Carrasco N. Thyroid Na+/I- symporter: mechanism, stoichiometry, and specificity. J Biol Chem 1997, 272:2723-2728.
24. Regalbuto C., Frasca F., Pellegriti G., et al. Update on thyroid cancer treatment. Future Oncol 2012, 8:1331-1348.
25. Mian C., Barollo S., Pennelli G., et al. Molecular characteristics in papillary thyroid cancers (PTCs) with no 131 I uptake. Clin Endocrinol 2008, 68:108-116.
26. Nikiforov Y.E. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med 2011, 135:569-577.
27. Xing M., Haugen B.R., Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013, 381:1058-1069.
28. Nikiforov Y.E. Molecular analysis of thyroid tumors. Mod Pathol 2011, 24:S34-S43.
29. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005, 12:245-262.
30. Cohen Y., Xing M., Mambo E., et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003, 95:625-627.
31. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nature 2013, 13:184-189.
32. Nikiforov Y.E., Nikiforova M.N. Molecular genetics and diagnosis of thyroid cancer. Nature 2011, 7:569-580.
33. Legakis I., Syrigos K. Recent advances in molecular diagnosis of thyroid cancer. J Thyroid Res 2011 2011, 1-8.
34. Xing M. Recent advances in molecular biology of thyroid cancer and their clinical implications. Otolaryngol Clin N Am 2008, 41:1135-1146.
35. Knauf J.A., Ma X., Smith E.P., et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 2005, 15(65(10)):4238-4245.
36. Fagin J.A. Challenging dogma in thyroid cancer molecular genetics-role of RET/PTC and BRAF in tumor initiation. J Clin Endocrinol Metab 2004, 89:4264-4266.
37. Cahill S., Smyth P., Finn S.P., et al. Effect of ret/PTC 1 rearrangement on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. Mol Cancer 2006, 5:1-12.
38. Santoro M., Dathan N.A., Berlingieri M.T., et al. Molecular characterization of RET/PTC3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. Oncogene 1994, 9(2):509-516.
39. Jhiang S.M., Sagartz J.E., Tong Q., et al. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 1996, 137:375-378.
40. Powell D.J., Russell J., Nibu K., et al. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res 1998, 58:5523-5528.
41. Celetti N., Cerrato A., Merolla F., Vitagliano D., Vecchio G., Grieco M. H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization. Oncogene 2004, 23:109-121.
42. Santoro M., Melillo R.M., Fusco A. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. European Journal of Endocrinology 2006, 155:645-653.
43. Sapio M.R., Guerra A., Marotta V., et al. High growth rate of benign thyroid nodules bearing RET/PTC rearrangements. J Clin Endocrinol Metab 2011, 96(6):E916-E919.
44. Salvatore G., Giannini R., Faviana P., et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 2004, 89(10):5175-5180.
45. Kondo T., Ezzat S., Asa S.L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006, 6:292-306.
46. Robinson M.J., Cobb M.H. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997, 9(2):180-186.
47. Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E., Fagin J.A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003, 63(7):1454-1457.
48. Soares P., Trovisco V., Rocha A.S., et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003, 22(29):4578-4580.
49. Frattini M., Ferrario C., Bressan P., et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 2004, 23(44):7436-7440.
50. Ciampi R., Nikiforov Y.E. Minireview: RET/PTC rearrangements and braf mutations in thyroid tumorigenesis. Endocrinology 2007, 148(3):936-941.
51. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892):949-954.
52. Hou P., Liu D., Xing M. Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. Endocr Relat Cancer 2007, 18:687-697.
53. Melillo R.M., Castellone M.D., Guarino V., et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005, 115:1068-1081.
54. Oler G., Camacho C.P., Hojaij F.C., Michaluart P., Riggins G.J., Cerutti J.M. Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis. Clin Cancer Res 2008, 14:4735-4742.
55. Palona I., Namba H., Mitsutake N., et al. BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor κB activation. Endocrinology 2006, 147:5699-5707.
56. Jo Y.S., Li S., Song J.H., et al. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 2006, 91:3667-3670.
57. Mesa C., Mirza M., Mitsutake N., et al. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res 2006, 66:6521-6529.
58. Mesa C., Mirza M., Mitsutake N., et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 2005, 24:6646-6656.
59. Kumagai A., Namba H., Mitsutake N., et al. Childhood thyroid carcinoma with BRAFT1799A mutation shows unique pathological features of poor differentiation. Oncol Rep 2006, 16:123-126.
60. Watanabe R., Hayashi Y., Sassa M., et al. Possible involvement of BRAFV600E in altered gene expression in papillary thyroid cancer. Endocr J 2009, 56:407-414.
61. Pasquali D., Santoro A., Bufo P., et al. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation. Thyroid 2011, 21:391-399.
62. Franzoni A., Dima M., D'Agostino M., et al. Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation. Thyroid 2009, 19:247-255.
63. Zerilli M., Zito G., Martorana A., et al. BRAF(V600E) mutation influences hypoxia-inducible factor 1α expression levels in papillary thyroid cancer. Mod Pathol 2010, 23:1052-1060.
64. Nucera C., Porrello A., Antonello Z.A., et al. B Raf(V600E) and thrombospondin 1 promote thyroid cancer progression. Proc Natl Acad Sci USA 2010, 107:54-1064.
65. Nowicki T.S., Kummer N.T., Iacob C., et al. Inhibition of uPAR and uPA reduces invasion in papillary thyroid carcinoma cells. Laryngoscope 2010, 120:1383-1390.
66. Nowicki T.S., Zhao H., Darzynkiewicz Z., et al. Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells. Cell Cycle 2011, 10:100-107.
67. Riesco-Eizaguirre G., Rodríguez I., De la Vieja A., et al. The BRAFV600E oncogene induces transforming growth factor β secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res 2009, 69:8317-8325.
68. Knauf J.A., Sartor M.A., Medvedovic M., et al. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene 2011, 30:3153-3162.
69. 131I uptake. Clin Endocrinol 2008, 68(1):108-116.
70. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501.
71. Xing M. Genetic alterations in the phosphatidylinositol 3 kinase/Akt pathway in thyroid cancer. Thyroid 2010, 20:697-706.
72. Saji M., Ringel M.D. The PI3K Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol 2010, 321:20-28.
73. Liaw D., Marsh D.J., Li J., et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997, 16:64-67.
74. Ringel M.D., Hayre N., Saito J., et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 2001, 61(16):6105-6111.
75. Vasko V., Saji M., Hardy E., et al. Akt activation and localisation correlate with tumor invasion and oncogene expression in thyroid cancer. J Med Genet 2004, 41(3):161-170.
76. Ringel M.D., Hayre N., Saito J., et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 2001, 61:6105-6111.
77. García-Rostán G., Costa A.M., Pereira-Castro I., et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 2005, 65(22):10199-10207.
78. Wu G., Mambo E., Guo Z., et al. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab 2005, 90(8):4688-4693.
79. Hou P., Liu D., Shan Y., et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 2007, 13(4):1161-1170.
80. Fresno Vara J.A., Casado E., de Castro J., Cejas P., Belda-Iniesta C., González-Barón M. P13K/Akt signaling pathway and cancer. Cancer Treat Rev 2004, 2(30):193-204.
81. Suzuki H., Willingham M.C., Cheng S.Y. Mice with a mutation in the thyroid hormone receptor βgene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid 2002, 12:963-969.
82. Furuya F., Hanover J.A., Cheng S.Y. Activation of phosphatidylinositol 3 kinase signaling by a mutant thyroid hormone β receptor. Proc Natl Acad Sci USA 2006, 103:1780-1785.
83. Vasko V., Saji M., Hardy E., et al. Akt activation and localisation correlate with tumor invasion and oncogene expression in thyroid cancer. J Med Genet 2004, 41:161-170.
84. Ricarte-Filho J.C., Ryder M., Chitale D.A., et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 2009, 69:4885-4893.
85. Saji M., Narahara K., McCarty S.K., et al. Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer. Oncogene 2011, 30:4307-4315.
86. Fagin J.A., Matsuo K., Karmakar A., Chen D.L., Tang S.H., Koeffler H.P. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993, 91(1):179-184.
87. Suarez H.G., du Villard J.A., Severino M., et al. Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 1990, 5:565-570.
88. Ezzat S., Zheng L., Kolenda J., Safarian A., Freeman J.L., Asa S.L. Prevalence of activating ras mutations in morphologically characterized thyroid nodules. Thyroid 1996, 6:409-416.
89. Meinkoth J.L. Biology of Ras in thyroid cells. Treat Res 2004, 122:131-148.
90. Esapa C.T., Johnson S.J., Kendall-Taylor P., Lennard T.W., Harris P.E. Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf) 1999, 50:529-535.
91. Motoi N., Sakamoto A., Yamochi T., Horiuchi H., Motoi T., Machinami R. Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin. Pathol Res Pract 2000, 196:1-7.
92. Manenti G., Pilotti S., Re F.C., Della Porta G., Pierotti M.A. Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. Eur J Cancer 1994, 30A:987-993.
93. Namba H., Rubin S.A., Fagin J.A. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 1990, 4:1474-1479.
94. Adeniran A.J., Zhu Z., Gandhi M., et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 2006, 30:216-222.
95. Zhu Z., Gandhi M., Nikiforova M.N., Fischer A.H., Nikiforov Y.E. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 2003, 120:71-77.
96. Lemoine N.R., Mayall E.S., Wyllie F.S., et al. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989, 4:159-164.
97. Basolo F., Pisaturo F., Pollina L.E., et al. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid 2000, 10(1):19-23.
98. Esapa C.T., Johnson S.J., Kendall-Taylor P., Lennard T.W., Harris P.E. Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol 1999, 50(4):529-535.
99. Motoi N., Sakamoto A., Yamochi T., Horiouchi H., Motoi T., Machinami R. Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin. Pathol Res Pract 2000, 196(1):1-7.
100. Rochefort P., Caillou B., Michiels F.M., et al. Thyroid pathologies in transgenic mice expressing a human activated Ras genedriven by a thyroglobulin promoter. Oncogene 1996, 12(1):111-118.
101. Kroll T.G., Sarraf P., Pecciarini L., et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science 2000, 289:1357-1360.
102. Wang Y., Hou P., Yu H., et al. High prevalence and mutual exclusivity of genetic alterations in the phosohatidiylinositol-3-kinase/Akt pathway in thyroid tumors. J Clin Endocrinol Metab 2007, 92(6):2387-2390.
103. Kroll T.G., Sarraf P., Pecciarini L., et al. PAX8-PPAR gamma1 fusion oncogene in human thyroid carcinoma. Science 2000, 289:1357-1360.
104. Gregory Powell J., Wang X., Allard B.L., et al. The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition. Oncogene 2004, 23:3634-3641.
105. Tallini G. Molecular pathobiology of thyroid neoplasms. Endocr Pathol 2002, 13(4):271-288.
106. Kroll T.G., Sarraf P., Pecciarini L., et al. PAX8-PPAR 1 fusion in oncogene human thyroid carcinoma. Science 2000, 289(5483):1357-1360.
107. Giordano T.J., Au A.Y., Kuick R., et al. Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin Cancer Res 1983, 12(7 Pt 1):93.
108. Reddi H.V., McIver B., Grebe S.K., Eberhardt N.L. The paired box-8/peroxisome proliferator-activated receptor-gamma oncogene in thyroid tumorigenesis. Endocrinology 2007, 148(3):932-935.
109. French C.A., Alexander E.K., Cibas E.S., et al. Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol 2003, 162:1053-1060.
110. Nikiforova M.N., Lynch R.A., Biddinger P.W., et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003, 88:2318-2326.
111. Dwight T., Thoppe S.R., Foukakis T., et al. Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab 2003, 88:4440-4445.
112. Nikiforova M.N., Biddinger P.W., Caudill C.M., Kroll T.G., Nikiforov Y.E. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 2002, 26:1016-1023.
113. Marques A.R., Espadinha C., Catarino A.L., et al. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 2002, 87:3947-3952.
114. Lui W.O., Zeng L., Rehrmann V., et al. CREB3L2-PPARgamma fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis. Cancer Res 2008, 68:7156-7164.
115. Farid N.R., Shi Y., Zou M. Molecular basis of thyroid cancer. Endocr Rev 1994, 15(2):202-232.
116. Segev D.L., Umbricht C., Zeiger M.A. Molecular pathogenesis of thyroid cancer. Surg Oncol 2003, 12(2):69-90.
117. Donghi R., Longoni A., Pilotti S., Michieli P., Della Porta G., Pierotti M.A. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 1993, 91(4):1753-1760.
118. Dobashi Y., Sugimura H., Sakamoto A., et al. Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas. Diagn Mol Pathol 1994, 3(1):9-14.
119. Ho Y.S., Tseng S.C., Chin T.Y., Hsieh L.L., Lin J.D. p53 gene mutation in thyroid carcinoma. Cancer Lett 1996, 103(1):57-63.
120. Takeuchi Y., Daa T., Kashima K., Yokoyama S., Nakayama I., Noguchi S. Mutations of p53 in thyroid carcinoma with an insular component. Thyroid 1999, 9(4):377-381.
121. Moretti F., Farsetti A., Soddu S., et al. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene 1997, 14(6):729-740.
122. Fagin J.A., Tang S.H., Zeki K., Di Lauro R., Fusco A., Gonsky R. Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53. Cancer Res 1996, 56(4):765-771.
123. Smallridge R.C., Marlow L.A., Copland J.A. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 2009, 16:17-44.
124. Nikiforov Y.E. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol 2004, 15:319-327.
125. Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 2010, 20:697-706.
126. La Perle K.M.D., Jhiang S.M., Capen C.C. Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. Am J Pathol 2000, 157(2):671-677.
127. Powell D.J., Russell J.P., Li G., et al. Altered gene expression in immunogenic poorly differentiated thyroid carcinomas fromRET/PTC3p53-/- mice. Oncogene 2001, 20(25):3235-3246.
128. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev 2007, 17:45-51.
129. Kraus C., Liehr T., Hülsken J., et al. Localization of the human beta-catenin gene (CTNNB1) to 3p21: a region implicated in tumor development. Genomics 1994, 23(1):272-274.
130. van Hengel J., Nollet F., Berx G., van Roy N., Speleman F., van Roy F. Assignment of the human beta-catenin gene (CTNNB1) to 3p22-p21.3 by fluorescence in situ hybridization. Cytogenet Cell Genet 1995, 70(1-2):68-70.
131. Garcia-Rostan G., Camp R.L., Herrero A., Carcangiu M.L., Rimm D.L., Tallini G. Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 2001, 158(3):987-996.
132. Miyake N., Maeta H., Horie S., et al. Absence of mutations in the beta-catenin and adenomatous polyposis coli genes in papillary and follicular thyroid carcinomas. Pathol Int 2001, 51(9):680-685.
133. Karin M. NF-κB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 2009, 1(5):000141.
134. Pacifico F., Mauro C., Barone C., et al. Oncogenic and anti-apoptotic activity of NF-κB in human thyroid carcinomas. J Bio Chem 2004, 279:5461-5469.
135. Visconti R., Cerutti J., Battista S., et al. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFκB p65 protein expression. Oncogene 1997, 15:1987-1994.
136. Mitsiades C.S., McMillin D., Kotoula V., et al. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab 2006, 91:4013-4021.
137. Pacifico F., Leonardi A. Role of NF-κB in thyroid cancer. Mol Cell Endocrinol 2010, 321:29-35.
138. Li X., Abdel-Mageed A.B., Mondal D., Kandil E. The nuclear factor κ-B signaling pathway as a therapeutic target against thyroid cancers. Thyroid 2012, Epub ahead of print.
139. Zhou Y.L., Liu C., Dai X., Zhang X.H., Wang O.C. Overexpression of miR-221 is associated with aggressive clinicopathologic characteristics and the BRAF mutation in papillary thyroid carcinomas. Med Oncol 2012, 29:3360-3366.
140. Greco A., Borrello M.G., Miranda C., Degl'Innocenti D., Pierotti M.A. Molecular pathology of differentiated thyroid cancer. Q J Nucl Med Mol Imaging 2009, 53(5):440-453.
141. Lu J., Getz G., Miska E.A., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
142. Volinia S., Calin G.A., Liu C.G., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci 2006, 103(7):2257-2261.
143. Pallante P., Visone R., Ferracin M., et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer 2006, 13:497-508.
144. Nikiforova M.N., Tseng G.C., Steward D., Diorio D., Nikiforov Y.E. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 2008, 93(5):1600-1608.
145. Schwertheim S., Sheu S.Y., Worm K., Grabellus F., Schmid K.W. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma. Horm Metab Res 2009, 41:475-481.
146. He H., Jazdzewski K., Li W., et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci 2005, 102(52):19075-19080.
147. Chou C.K., Chen R.F., Chou F.F., et al. miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. Thyroid 2010, 20(5):489-494.
148. Wang S., Wuu J., Savas L., Patwardhan N., Khan A. The role of cell cycle regulatory proteins, cyclin D1, cyclin E, and p27 in thyroid carcinogenesis. Hum Pathol 1998, 29(11):1304-1309.
149. Chou C.K., Yang K.D., Chou F.F., et al. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma. J Clin Endocrinol Metab 2013, 98(2):E196-E205.
150. Geraldo M.V., Yamashita A.S., Kimura E.T. MicroRNA miR-146b-5p regulates signal transduction of TGF-β by repressing SMAD4 in thyroid cancer. Oncogene 2012, 31:1910-1922.
151. Wang Z., Zhang H., He L., et al. Association between the expression of four upregulated miRNAs and extrathyroidal invasion in papillary thyroid carcinoma. Onco Targets Ther 2013, 6:281-287.
152. Wang Z., Zhang H., Zhang P., Li J., Shan Z., Teng W. Upregulation of miR-2861 and miR-451 expression in papillary thyroid carcinoma with lymph node metastasis. Med Oncol 2013, 30:577.
153. Yu S., Liu Y., Wang J., et al. Circulating MicroRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 2012, 97(6):2084-2092.
154. Pallante P., Visone R., Croce C.M., Fusco A. Deregulation of microRNA expression in follicular cell-derived human thyroid carcinomas. Endocr Relat Cancer 2010, 17:F91-F104.
155. Castellone M.D., Guarino V., De Falco V., et al. Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. Oncogene 2004, 23:5958-5967.
156. Weber F., Teresi R.E., Broelsch C.E., Frilling A., Eng C. A limited set of human microRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab 2006, 91:3584-3591.
157. Argraves W.S., Greene L.M., Cooley M.A., Gallagher W.M. Fibulins: physiological and disease perspectives. EMBO Rep 2003, 4:1127-1131.
158. Schulte K.M., Jonas C., Krebs R., Roher H.D. Activin A and activin receptors in thyroid cancer. Thyroid 2001, 11:3-14.
159. Boucheix C., Duc G.H., Jasmin C., Rubinstein E. Tetraspanins and malignancy. Expert Rev Mol Med 2001 2001, 1-17.
160. Choi K.S., Bae M.K., Jeong J.W., Moon H.E., Kim K.W. Hypoxia-induced angiogenesis during carcinogenesis. J Biochem Mol Biol 2003, 36:120-127.
161. Burrows N., Resch J., Cowen R.L., et al. Expression of hypoxia-inducible factor 1α in thyroid carcinomas. Endocr Relat Cancer 2010, 17:61-72.
162. Scarpino S., Cancellario d'Alena F., Di Napoli A., Pasquini A., Marzullo A., Ruco L.P. Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumor cells in papillary carcinoma of the thyroid. J Pathol 2004, 202:352-358.
163. Mo J.H., Choi I.J., Jeong W.J., Jeon E.H., Ahn S.H. HIF-1α and HSP90: target molecules selected from a tumorigenic papillary thyroid carcinoma cell line. Cancer Sci 2012, 103(3):464-471.
164. Burrows N., Babur M., Resch J., et al. GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia inducible factor-1α (HIF-1α) pathways. J Clin Endocrinol Metab 2011, 96:e1934-e1943.
165. Zerilli M., Zito G., Martorana A., et al. BRAF(V600E) mutation influences hypoxia-inducible factor-1α expression levels in papillary thyroid cancer. Mod Pathol 2010, 23(8):1052-1060.
166. Burrows N., Babur M., Resch J., et al. GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1α (HIF-1α) pathways. Clin Endocrinol Metab 2011, 96(12):E1934-E1943.
167. Koperek O., Bergner O., Pichlhöfer B., et al. Expression of hypoxia-associated proteins in sporadic medullary thyroid cancer is associated with desmoplastic stroma reaction and lymph node metastasis and may indicate somatic mutations in the VHL gene. J Pathol 2011, 225(1):63-72.
168. Xing M. Gene methylation in thyroid tumorigenesis. Endocrinology 2007, 148:948-953.
169. Hu S., Liu D., Tufano R.P., et al. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer 2006, 119:2322-2329.
170. Hou P., Liu D., Xing M. Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. Endocr Relat Cancer 2011, 18:687-697.
171. Hou P., Ji M., Xing M. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer 2008, 113:2440-2447.
172. Alvarez-Nuñez F., Bussaglia E., Mauricio D., et al. PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid 2006, 16:17-23.
173. Frisk T., Foukakis T., Dwight T., et al. Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer. Genes Chromosomes Cancer 2002, 35:74-80.
174. Bruni P., Boccia A., Baldassarre G., et al. PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTENgrowth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene 2000, 19:3146-3155.
175. Cibas E.S., Ali S.Z. The Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol 2009, 132:658-665.
176. Fassina A.S., Montesco M.C., Ninfo V., Denti P., Masarotto G. Histological evaluation of thyroid carcinomas: reproducibility of the "WHO" classification. Tumori 1993, 79:314-320.
177. Franc B., de la Salmoniere P., Lange F., et al. Interobserver and intraobserver reproducibility in the histopathology of follicular thyroid carcinoma. Hum Pathol 2003, 34:1092-1100.
178. Eszlinger M., Krohn K., Hauptmann S., Dralle H., Giordano T.J., Paschke R. Perspectives for improved and more accurate classification of thyroid epithelial tumors. J Clin Endocrinol Metab 2008, 93:3286-3294.
179. Faggiano A., Caillou B., Lacroix L., et al. Functional characterization of human thyroid tissue with immunohistochemistry. Thyroid 2007, 17:203-211.
180. Fusco A., Santoro M. 20 years of RET/PTC in thyroid cancer: clinic-pathological correlations. Arq Bras Endocrinol Metab 2007, 51:731-735.
181. Marotta V., Guerra A., Sapio M.R., Vitale M. RET/PTC rearrangement in benign and malignant thyroid disease: a clinical standpoint. Eur J Endocrinol 2011, 165:499-507.
182. Clark D.P. Molecular diagnostics on thyroid fine-needle aspirations. Cancer Cytopathol 2010, 25:14-16.
183. Fusco A., Grieco M., Santoro M., et al. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 1987, 328:170-173.
184. Grieco M., Santoro M., Berlingieri M.T., et al. PTC is a novel rearranged form of the RET proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990, 60:557-563.
185. Santoro M., Melillo R.M., Fusco A. RET/PTC activation in papillary thyroid carcinoma. Eur J Endocrinol 2006, 155:645-653.
186. Chiappetta G., Toti P., Cetta F., et al. The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hürthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. J Clin Endocrinol Metab 2002, 87:364-369.
187. Rhoden K.J., Unger K., Salvatore G., et al. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab 2006, 91:2414-2423.
188. Guerra A., Sapio M.R., Marotta V., et al. Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application. Endocr J 2011, 58:31-38.
189. Marotta V., Guerra A., Sapio M.R., et al. Growing thyroid nodules with benign histology and RET rearrangement. Endocr J 2010, 57:1081-1087.
190. Sapio M.R., Guerra A., Marotta V., et al. High growth rate of benign thyroid nodules bearing RET/PTC rearrangements. J Clin Endocrinol Metab 2011, 96:E916-E919.
191. Tallini G., Santoro M., Helie M., et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 1998, 4:287-294.
192. Thomas G.A., Bunnell H., Cook H.A., et al. High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. J Clin Endocrinol Metab 1999, 84:4232-4238.
193. Rabes H.M., Demidchik E.P., Sidorow J.D., et al. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-Chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin Cancer Res 2000, 6:1093-1103.
194. Elisei R., Romei C., Vorontsova T., et al. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated malignant and benign thyroid lesions in children and adults,. J Clin Endocrinol Metab 2001, 86(7):3211-3216.
195. Fusco A., Chiappetta G., Hui P., et al. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am J Pathol 2002, 160(6):2157-2167.
196. Nikiforov Y.E., Steward D.L., Robinson-Smith T.M., et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009, 94(6):2092-2098.
197. Cantara S., Capezzone M., Marchisotta S., et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab 2010, 95:1365-1369.
198. Pizzolanti G., Russo L., Richiusa P., et al. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAFV600E mutation and RET/PTC rearrangement. Thyroid 2007, 17:1109-1115.
199. Tufano R.P., Teixeira G.V., Bishop J., Carson K.A., Xing M. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine 2012, 91:274-286.
200. Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 2010, 321:86-93.
201. Xing M., Westra W.H., Tufano R.P., et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005, 90:6373-6379.
202. Romei C., Ciampi R., Faviana P., et al. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer 2008, 15:511-520.
203. Jin L., Sebo T.J., Nakamura N., et al. BRAF mutation analysis in fine needle aspiration (FNAB) cytology of the thyroid. Diagn Mol Pathol 2006, 15:136-143.
204. Cohen Y., Rosenbaum E., Clark D.P., et al. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 2004, 10:2761-2765.
205. Sapio M.R., Posca D., Raggioli A., et al. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocrinol (Oxf) 2007, 66(5):678-683.
206. Pizzolanti G., Russo L., Richiusa P., et al. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF(V600E) mutation and RET/PTC rearrangement. Thyroid 2007, 17:1109-1115.
207. Nikiforova M.N., Nikiforov Y.E. Molecular diagnostics and predictors in thyroid cancer. Thyroid 2009, 19:61.
208. Kim S.K., Hwang T.S., Yoo Y.B., et al. Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J Clin Endocrinol Metab 2011, 96:658-664.
209. Kim S.W., Lee J.I., Kim J.W., et al. BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population. J Clin Endocrinol Metab 2010, 95:3693-3700.
210. Rowe L.M., Bentz B.M., Bentz J.M. Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal 2006, 3:10.
211. Ohori N.P., Nikiforov M.N. Contribution of molecular testing to thyroid fine needle aspiration cytology of follicular lesion of undeterminated significance/atypia of underdetermined significance. Cancer (Cytopathology) 2010, 118:17-23.
212. Moses W., Weng J., Sansano I., et al. Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World J Surg 2010, 34:2589-2594.
213. Cooper D.S., Doherty G.M., Haugen B.R., et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19:1167-1214.
214. Baloch Z.W., LiVolsi V.A., Asa S.L., et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 2008, 36:425-437.
215. Lubitz C.C., Fahey T.J. The differentiation of benign and malignant thyroid nodules. Adv Surg 2005, 39:355-377.
216. Prasad N.B., Somervell H., Tufano R.P., et al. Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin Cancer Res 2008, 14:3327-3337.
217. Belge G., Meyer A., Klemke M., et al. Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias. Genes Chromosomes Cancer 2008, 47:656-663.
218. Chiappetta G., Ferraro A., Vuttariello E., et al. HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. Eur J Cancer 2008, 44:1015-1021.
219. Lappinga P.J., Kip N.S., Jin L., et al. HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules. Cancer Cytopathol 2010, 118:287-297.
220. Griffith O.L., Melck A., Jones S.J.M., Wiseman S.M. Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. J Clin Oncol 2006, 24:5043-5051.
221. Chudova D., Wilde J.I., Wang E.T., et al. Molecular classification of thyroid nodules using high-dimensionality genomic data. J Clin Endocrin Metab 2010, 95:5296-5304.
222. Mathur A., Weng J., Moses W., et al. A prospective study evaluating the accuracy of using combined clinical factors and candidate diagnostic markers to refine the accuracy of thyroid fine needle aspiration biopsy. Surgery 2010, 148:1170-1176.
223. Nikiforova M.N., Chiosea S.I., Nikiforov Y.E. MicroRNA expression profiles in thyroid tumors. Endocr Pathol 2009, 20:85-91.
224. Wan P.T., Garnett M.J., Roe S.M., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116(6):855-867.
225. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64(19):7099-7109.
226. Salvatore G., De Falco V., Salerno P., et al. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 2006, 12(5):1623-1629.
227. Carlomagno F., Anaganti S., Guida T., et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006, 98:326-334.
228. Baudin E., Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 2007, 8:148-156.
229. Espinosa A.V., Porchia L., Ringel M.D. Targeting BRAF in thyroid cancer. Br J Cancer 2007, 96:16-20.
230. Ouyang B., Knauf J.A., Smith E.P., et al. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res 2006, 12:1785-1793.
231. Solit D.B., Garraway L.A., Pratilas C.A., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
232. Herbst R.S., Heymach J.V., O'Reilly M.S., Onn A., Ryan A.J. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Invest Drugs 2007, 16:239-249.
233. Carlomagno F., Vitagliano D., Guida T., et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002, 62(24):7284-7290.
234. Santoro M., Carlomagno F. Drug insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nat Clin Pract Endocrinol Metab 2006, 2(1):42-52.
235. Carlomagno F., Guida T., Anaganti S., et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 2004, 23:6056-6063.
236. Pao W., Miller V.A. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005, 23:2556-2568.
237. Kim D.W., Jo Y.S., Jung H.S., et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocr Metab 2006, 91:4070-4076.
238. Carlomagno F., Vitagliano D., Guida T., et al. The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res 2002, 62:1077-1082.
239. Carlomagno F., Vitagliano D., Guida T., et al. Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). J Clin Endocrinol Metab 2003, 88:1897-1902.
240. Garcia-Rostan G., Zhao H., Camp R.L., et al. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 2003, 21:3226-3235.
241. Fagin J.A. Minireview: branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol Endocrinol 2002, 16:903-911.
242. Saavedra H.I., Knauf J.A., Shirokawa J.M., et al. The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene 2000, 19:3948-3954.
243. Sansal I., Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004, 22(14):63.
244. Furuya F., Lu C., Willingham M.C., Cheng S.Y. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Carcinogenesis 2007, 28(12):2451-2458.
245. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009, 8(8):627-644.
246. Placzkowski K.A., Reddi H.V., Grebe S.K., Eberhardt N.L., McIver B. The role of the PAX8/PPARgamma fusion oncogene in thyroid cancer. PPAR Res 2008, 2008:672829.
247. Karin M. NF-κB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 2009, 1(5):41.
248. Liu D., Xing M. Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-κB pathways. Thyroid 2008, 18(8):853-864.
249. Xing M. Minireview: gene methylation in thyroid tumorigenesis. Endocrinology 2007, 148(3):948-953.
250. Akagi T., Luong Q.T., Gui D., et al. Induction of sodium iodide symporter gene and molecular characterisation of HNF3β/FoxA2, TTF-1 and C/EBPβ in thyroid carcinoma cells. Br J Cancer 2008, 99(5):781-788.
251. Kouzarides T. Chromatin modifications their function. Cell 2007, 128(4):693-705.
252. Ting A.H., McGarvey K.M., Baylin S.B. The cancer epigenome-components and functional correlates. Genes Dev 2006, 20(23):3215-3231.
253. Riesco-Eizaguirre G., Santisteban P. New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. Endocr Relat Cancer 2007, 14(4):957-977.
254. Lim S.M., Chang H., Yoon M.J., et al. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. Ann Oncol 2013, 24(12):3089-3094.
255. Ball D.W., Sherman S.I., Jarzab B., et al. Lenvatinib treatment of advanced RAI-refractory differentiated thyroid cancer (DTC): cytokine and angiogenic factor (CAF) profiling in combination with tumor genetic analysis to identify markers associated with response. J Clin Oncol 2012, 30(15):5518.
256. Pennell N.A., Daniels G.H., Haddad R.I., et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 2008, 18(3):317-323.
257. Sherman E.J., Fury M.G., Tuttle R.M., et al. Phase II study of depsipeptide (DEP) in radioiodine (RAI)-refractory metastatic nonmedullary thyroid carcinoma. J Clin Oncol 2009, 27(15S):6059.
258. Woyach J.A., Kloos R.T., Ringel M.D., et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab 2009, 94(1):164-170.
259. Cohen E.E., Rosen L.S., Vokes E.E., et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008, 26(29):4708-4713.
260. Gupta-Abramson V., Troxel A.B., Nellore A., et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008, 26(29):4714-4719.
261. Kelly W.K., O'Connor O.A., Krug L.M., et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005, 23(17):3923-3931.
262. Sherman S.I., Wirth L.J., Droz J.P., et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008, 359(1):31-42.
263. Ain K.B., Lee C., Williams K.D., Phase I.I. trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid 2007, 17(7):663-670.
264. Bible K.C., Suman V.J., Molina J.R., et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010, 11(10):962-972.
265. Zhang Y., Guessous F., Kofman A., Schiff D., Abounader R. XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs 2010, 13(2):112-121.
266. de Groot J.W., Zonnenberg B.A., van Ufford-Mannesse P.Q., et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 2007, 92(9):3466-3469.
267. Mrozek E., Kloos R.T., Ringel M.D., et al. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006, 91(6):2201-2204.
268. Cooney M.M., Savvides P., Agarwala S., et al. Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC). J Clin Oncol 2006, 24(18).
269. Cohen E.E., Needles B.M., Cullen K.J., et al. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 2008, 26(15):6025.
270. Wells S.A., Robinson B.G., Gagel R.F., et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012, 30(2):134-141.
271. Wells S.A., Gosnell J.E., Gagel R.F., et al. Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial. J Clin Oncol 2007, 25(18):6018.
272. Ain K.B., Lee C., Holbrook K.M., Dziba J.M., Williams K.D. Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: preliminary results. J Clin Oncol 2008, 26(15):6027.
273. Elisei R., Schlumberger M.J., Müller S.P., et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013, 31(29):3639-3646.
274. Meier C.A., Braverman L.E., Ebner S.A., et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 1994, 78(1):188-196.
275. Mooney C.J., Nagaiah G., Fu P., et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 2009, 19(3):233-240.
276. Piekarz R., Luchenko V., Draper D., et al. Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers. J Clin Oncol 2008, 26(15):3571.
277. Argiris A., Agarwala S.S., Karamouzis M.V., Burmeister L.A., Carty S.E. A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer. Invest New Drugs 2008, 26(2):183-188.
278. Kebebew E., Peng M., Reiff E., et al. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 2006, 140(6):960-966.
279. http://www.clinicaltrials.gov/.
280. Liu D., Xing J., Trink B., Xing M. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer 2010, 127(12):2965-2973.
281. Jin N., Jiang T., Rosen D.M., Nelkin B.D., Ball D.W. Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. Clin Cancer Res 2013, 17(20):6482-6489.
282. Liu R., Liu D., Xing M. The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells. J Clin Endocrinol Metab 2012, 97(2):E173-E182.
283. Xing M. Genetic-targeted therapy of thyroid cancer: a real promise. Thyroid 2009, 19(8):805-809.
284. Kloos R.T., Ringel M.D., Knopp M.V., et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009, 27(10):1675-1684.
285. Ahmed M., Barbachano Y., Riddell A., et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol 2011, 165(2):315-322.
286. Flaherty K.T., Puzanov I., Kim K.B., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363(9):809-819.
287. Hou P., Bojdani E., Xing M. Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways. J Clin Endocrinol Metab 2010, 95(2):820-828.